

# CITATION REPORT

List of articles citing

## SGLT-2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects

DOI: 10.1161/jaha.119.013389

Journal of the American Heart Association, 2019, 8, e013389.

**Source:** <https://exaly.com/paper-pdf/72329885/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
107	SGLT-2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects. <i>Journal of the American Heart Association</i> , <b>2019</b> , 8, e013389	6	78
106	Twelve-year trends in pharmacologic treatment of type 2 diabetes among patients with heart failure in the United States. <b>2020</b> , 22, 705-710		3
105	Characterization of left ventricular myocardial sodium-glucose cotransporter 1 expression in patients with end-stage heart failure. <b>2020</b> , 19, 159		14
104	What Makes Sodium-Glucose Co-Transporter-2 Inhibitors Stand out in Heart Failure?. <b>2020</b> , 20, 63		3
103	Polypharmacy in Older Adults Hospitalized for Heart Failure. <b>2020</b> , 13, e006977		25
102	Ageing-associated increase in SGLT2 disrupts mitochondrial/sarcoplasmic reticulum Ca homeostasis and promotes cardiac dysfunction. <b>2020</b> , 24, 8567-8578		11
101	Cardiometabolic phenotype of heart failure with preserved ejection fraction as a target of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide receptor agonists. <b>2021</b> , 117, 1992-1994 <sup>1</sup>		1
100	Cardiometabolic risk factor control in black and white people in the United States initiating sodium-glucose co-transporter-2 inhibitors: A real-world study. <b>2020</b> , 22, 2384-2397		2
99	Natriuresis, Diuresis, and Volume Changes in Diabetics With Heart Failure With Preserved Ejection Fraction: Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Natriuretic Peptides. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e017666	6	0
98	The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection. <b>2021</b> , 53, 2072-2089		10
97	Novel roles of immunometabolism and nonmyocyte metabolism in cardiac remodeling and injury. <b>2020</b> , 319, R476-R484		2
96	Sodium-coupled glucose transport, the SLC5 family, and therapeutically relevant inhibitors: from molecular discovery to clinical application. <b>2020</b> , 472, 1177-1206		13
95	Role of sodium glucose co-transporter 2 inhibitors in patients with heart failure: an elusive mechanism. <b>2020</b> , 52, 178-190		0
94	SGLT2 Inhibitors: the Star in the Treatment of Type 2 Diabetes?. <b>2020</b> , 8,		13
93	Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review. <b>2020</b> , 5, 632-644		136
92	Mitochondrial ROS Formation in the Pathogenesis of Diabetic Cardiomyopathy. <b>2020</b> , 7, 12		74
91	Evaluation and management of heart failure with preserved ejection fraction. <b>2020</b> , 17, 559-573		113

90	Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial. <b>2020</b> , 43, 1356-1359	48
89	Basic and Clinical Pharmaco-Therapeutics of SGLT2 Inhibitors: A Contemporary Update. <b>2020</b> , 11, 813-833	9
88	Prevention of heart failure with preserved ejection fraction (HFpEF): reexamining microRNA-21 inhibition in the era of oligonucleotide-based therapeutics. <b>2020</b> , 49, 107243	5
87	Sodium glucose cotransporter2 inhibitor-possible treatment for patients with diabetes, pulmonary disease and CO retention. <b>2020</b> , 139, 109631	2
86	Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial. <b>2020</b> , 22, 1141-1150	9
85	Tackling myocardial oxidative stress with empagliflozin: are we big enough to fight heart failure with preserved ejection fraction?. <b>2021</b> , 117, 343-345	0
84	Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure. <b>2021</b> , 26, 603-622	4
83	Cost-utility analysis of add-on dapagliflozin treatment in heart failure with reduced ejection fraction. <b>2021</b> , 322, 183-190	12
82	The Potential of Albuminuria as a Biomarker of Diabetic Complications. <b>2021</b> , 35, 455-466	5
81	SGLT2-inhibitors; more than just glycosuria and diuresis. <b>2021</b> , 26, 623-642	14
80	Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function. <b>2021</b> , 83, 503-528	25
79	Renal dysfunction in cardiovascular diseases and its consequences. <b>2021</b> , 34, 137-153	13
78	Sex Differences in Right Ventricular Dysfunction: Insights From the Bench to Bedside. <b>2020</b> , 11, 623129	4
77	SGLT2 inhibitors - A new silver bullet. <b>2021</b> , 62, 99-100	
76	Proteostasis of Islet Amyloid Polypeptide: A Molecular Perspective of Risk Factors and Protective Strategies for Type II Diabetes. <b>2021</b> , 121, 1845-1893	38
75	Examining the Role of Novel CKD Therapies for the ADPKD Patient.. <b>2021</b> , 2, 1036-1041	1
74	A Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease. <b>2021</b> , 16, e11	1
73	Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial. <b>2021</b> , 233, 141-148	10

72	The role of SGLT2 inhibitors beyond glucose-lowering to cardio-renal protection. <b>2021</b> , 26, 4323	
71	Combining sodium-glucose cotransporter 2 inhibitors and angiotensin receptor-neprilysin inhibitors in heart failure patients with reduced ejection fraction and diabetes mellitus: A multi-institutional study. <b>2021</b> , 330, 91-97	4
70	Mechanisms and Models in Heart Failure: A Translational Approach. <b>2021</b> , 128, 1435-1450	6
69	Epigenetic Therapies for Heart Failure: Current Insights and Future Potential. <b>2021</b> , 17, 247-254	6
68	Eligibility of outpatients with chronic heart failure for sodium-glucose co-transporter-2 inhibitors. <b>2021</b> , 8, 2951-2958	4
67	Extra-cardiac targets in the management of cardiometabolic disease: Device-based therapies. <b>2021</b> , 8, 3327-3338	3
66	Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension. <b>2021</b> , 39, 1522-1545	7
65	A Review of the Role of Type 2 Diabetes and SGLT2 Inhibitors in Heart Failure with Preserved Ejection Fraction. <b>2021</b> ,	0
64	HbA1c and FIB-4 as Serologic Markers for the Risk of Progression of Stage A Heart Failure.	
63	Phenotyping the Prediabetic Population-A Closer Look at Intermediate Glucose Status and Cardiovascular Disease. <b>2021</b> , 22,	2
62	Management of heart failure with reduced ejection fraction in 2021: an update for GPs. <b>2021</b> , 71, 330-332	
61	Impact of the initial decline in estimated glomerular filtration rate on the risk of new-onset atrial fibrillation and adverse cardiovascular and renal events in patients with type 2 diabetes treated with sodium-glucose co-transporter-2 inhibitors. <b>2021</b> , 23, 2077-2089	1
60	Vericiguat for the treatment of heart failure: mechanism of action and pharmacological properties compared with other emerging therapeutic options. <b>2021</b> , 22, 1847-1855	4
59	The Mystery of Diabetic Cardiomyopathy: From Early Concepts and Underlying Mechanisms to Novel Therapeutic Possibilities. <b>2021</b> , 22,	6
58	Euglycemic Diabetic Ketoacidosis After Cardiac Surgery in a Patient Treated With Empagliflozin for Type 2 Diabetes Mellitus: A Case Report. <b>2021</b> ,	1
57	Anti-arrhythmic and inotropic effects of empagliflozin following myocardial ischemia. <b>2021</b> , 276, 119440	6
56	Sodium-glucose cotransporter 2 inhibitor effects on heart failure hospitalization and cardiac function: systematic review. <b>2021</b> , 8, 4093-4118	2
55	SGLT2 inhibitors: What role do they play in heart failure with reduced ejection fraction?. <b>2021</b> , 46, 30-37	0

54	Cardioprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors Regardless of Type 2 Diabetes Mellitus: A Meta-analysis. <b>2021</b> ,	
53	Overview of Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitors for the Treatment of Non-diabetic Heart Failure Patients. <b>2021</b> , 13, e17118	0
52	Update on the Cardiovascular Benefits of Sodium-Glucose Co-Transporter-2 Inhibitors: Mechanism of Action, Available Agents and Comprehensive Review of Literature. <b>2021</b> , 12, 210-218	2
51	The Role of SGLT2 Inhibitors in Heart Failure: A Systematic Review and Meta-Analysis. <b>2021</b> , 2021, 9927533	2
50	Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. <b>2021</b> , 56, 951-963	14
49	Sodium-Glucose Cotransporter-2 Inhibitor Use is Associated with a Reduced Risk of Heart Failure Hospitalization in Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus: A Real-World Study on a Diverse Urban Population. <b>2021</b> , 1	2
48	Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. <b>2021</b> , 51, 1013-1025	7
47	Positive Inotropic Drugs for Treating Heart Failure. <b>2021</b> ,	
46	Genetic Variation in Sodium-glucose Cotransporter 2 and Heart Failure. <b>2021</b> , 110, 149-158	4
45	Sodium-glucose cotransporter 2 inhibitors mechanisms of action in heart failure. <b>2020</b> , 11, 269-279	8
44	DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure. <b>2020</b> , 9,	9
43	The role of parasympathetic mechanisms in the infarct-limiting effect of SGLT2 inhibitor ertugliflozin.	
42	Towards quadruple therapy for heart failure with reduced ejection fraction: DAPA-HF secondary analysis data. <b>2020</b> , 25, 3870	3
41	Comprehensive evaluation of cardiovascular efficacy and safety outcomes of SGLT2 inhibitors in high risk patients of cardiovascular disease: systematic review and meta-analysis. <b>2021</b> , 10, 89-98	3
40	Endocrine system dysfunction and chronic heart failure: a clinical perspective. <b>2021</b> , 1	1
39	Prevention of Heart Failure. <b>2021</b> , 489-512	
38	Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease. <b>2021</b> , 611-651	
37	Heart Failure Therapies for the Prevention of HER2-Monoclonal Antibody-Mediated Cardiotoxicity: A Systematic Review and Meta-Analysis of Randomized Trials. <b>2021</b> , 13,	0

36	The SGLT-2 Inhibitors in Personalized Therapy of Diabetes Mellitus Patients.. <b>2021</b> , 11,	1
35	New Approaches to Cardiovascular Disease and its Management in Kidney Transplant Recipients. <b>2021</b> ,	1
34	From salt to hypertension, what is missed?. <b>2021</b> , 23, 2033	2
33	Current perspectives of the use of Sodium Glucose Transport-2 Inhibitors for patients with heart failure and chronic kidney disease. <b>2021</b> ,	
32	Egyptian expert opinion for the use of sodium-glucose cotransporter-2 inhibitors in patients with heart failure with reduced ejection fraction.. <b>2022</b> ,	1
31	Effects of canagliflozin and metformin on insulin resistance and visceral adipose tissue in people with newly-diagnosed type 2 diabetes.. <b>2022</b> , 22, 37	0
30	Congestive Nephropathy.. <b>2022</b> , 19,	0
29	Alternate day add on therapy with dapagliflozin in patients with type 2 diabetes mellitus: potential benefits and concerns.. <b>2022</b> ,	0
28	Bacterial diversity in the intestinal mucosa of heart failure rats treated with Sini Decoction.. <b>2022</b> , 22, 93	
27	Diabetes Mellitus, Race, and Effects of Omega-3 Fatty Acids on Incidence of Heart Failure Hospitalization.. <b>2022</b> , 10, 227-234	0
26	SGLT-2 Inhibitor Use in Heart Failure: A Review for Nurses.. <b>2022</b> , 45, 189-198	0
25	Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review. <b>2021</b> , 39, 845	2
24	SGLT-2 INHIBITORS [AN ANTIDIABETIC WITH CARDIOPROTECTIVE EFFECTS. <b>2021</b> , 50-52	
23	Chronic heart failure [modification of treatment paradigm. <b>2022</b> , 24, 13-19	1
22	Sodium-Glucose Cotransporter-2 Inhibitors Improve Heart Failure with Reduced Ejection Fraction Outcomes by Reducing Edema and Congestion.. <b>2022</b> , 12,	1
21	Association of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Use With Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus Patients With Stabilized Acute Myocardial Infarction: A Propensity Score Matching Study.. <b>2022</b> , 9, 882181	0
20	Luseogliflozin inhibits high glucose-induced TGF-2 expression in mouse cardiomyocytes by suppressing NHE-1 activity.. <b>2022</b> , 50, 3000605221097490	0
19	The Effects of Sodium-Glucose Cotransporter-2 Inhibitors (SLGT-2i) on Cardiovascular and Renal Outcomes in Non-diabetic Patients: A Systematic Review. <b>2022</b> ,	

18	Risk of sepsis and pneumonia in patients initiated on SGLT2 inhibitors and DPP-4 inhibitors. <b>2022</b> , 101367	1
17	Sodium-glucose cotransporter 2 inhibitor-associated severe epididymo-orchitis. <b>2022</b> , 15, e250942	0
16	Evaluation of Loop Diuretic Dosing Following Sodium-Glucose Cotransporter 2 Inhibitor Initiation in Patients With Heart Failure. 089719002211161	
15	The New Role of SGLT2 Inhibitors in the Management of Heart Failure: Current Evidence and Future Perspective. <b>2022</b> , 14, 1730	3
14	Empagliflozin improves cardiac mitochondrial function and survival through energy regulation in a murine model of heart failure.. <b>2022</b> , 931, 175194	0
13	Comments on: "Secondary prevention implantable cardioverter-defibrillator (ICD) therapy: value in octogenarians".	0
12	SGLT2 inhibitors DELIVER benefits in heart failure independently of ejection fraction and diabetes: end of the line or need for new studies?.	0
11	Influence of diabetes on sacubitril/valsartan titration and clinical outcomes in patients hospitalized for heart failure.	0
10	Sodium-glucose cotransporter 2 inhibitors and the risk of pneumonia and septic shock: A systematic review and meta-analysis.	1
9	Metabolomic analysis of the effect of canagliflozin on HFpEF rats and its underlying mechanism.	0
8	Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes.	0
7	The Efficiency of Background Data Visualization of College Smart Education System Integrating Social Management Information Platform. <b>2022</b> ,	0
6	Treatment of HFpEF beyond the SGLT2-Is: Does the Addition of GLP-1 RA Improve Cardiometabolic Risk and Outcomes in Diabetic Patients?. <b>2022</b> , 23, 14598	0
5	Clinical benefit of sodium-glucose transport protein-2 inhibitors in patients with heart failure: An updated meta-analysis and trial sequential analysis. 9,	0
4	Reflecting on the advancements of HFpEF therapies over the last two decades and predicting what is yet to come. <b>2022</b> , 24, L2-L9	0
3	Medications for When the Heart Fails. <b>2023</b> ,	0
2	In search of mechanisms to explain the unquestionable benefit derived from sodium-glucose cotransporter-2 (SGLT-2) inhibitors use in heart failure patients. <b>2023</b> , 135, 323-326	0
1	Novel Oxidative Stress Biomarkers with Risk Prognosis Values in Heart Failure. <b>2023</b> , 11, 917	0

